
DNALite
An early-stage preclinical biotechnology company that is making DNA based gene-therapy drugs for the gastrointestinal (GI) tract by leveraging new drug delivery technologies.
Employees
Enterprise value
$36—54m
Authorizing premium user...
An early-stage preclinical biotechnology company that is making DNA based gene-therapy drugs for the gastrointestinal (GI) tract by leveraging new drug delivery technologies.